Cidara Therapeutics Acquired by Merck for $221.50 Per Share; Delisting Imminent

summarizeSummary

Merck has successfully completed its tender offer for Cidara Therapeutics at $221.50 per share, leading to Cidara's delisting from Nasdaq as it becomes a wholly-owned subsidiary.

check_boxKey Events

• Acquisition Completed

  Merck's subsidiary, Caymus Purchaser, Inc., successfully completed its cash tender offer for all outstanding shares of Cidara Therapeutics, Inc.

• Offer Price Confirmed

  Common shares were acquired for $221.50 per share, with the offer expiring on January 6, 2026.

• Delisting and Deregistration

  Cidara's common stock is expected to cease trading on Nasdaq prior to the opening of business on January 7, 2026, and will be delisted and deregistered.

• Strategic Rationale

  The acquisition strengthens Merck's respiratory portfolio, integrating Cidara's CD388, a potentially first-in-class, long-acting antiviral.

auto_awesomeAnalysis

The completion of the tender offer and subsequent merger by Merck marks the end of Cidara Therapeutics as an independent publicly traded company. Shareholders who tendered their shares will receive $221.50 per common share. The acquisition, valued at approximately $9.0 billion in R&D expenses for Merck, integrates Cidara's CD388 antiviral into Merck's respiratory portfolio. Investors should be aware that Cidara's common stock will cease trading and be delisted from Nasdaq, converting remaining shares into the right to receive the offer price.